Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Thursday, July 9, 2026

Snapshot: Jul 9, 2026 · 6:00 PM 100 stocks analyzed

Up Day

Thu, Jul 9, 2026 Divergent Normal

S&P 500 up 0.8% on broad small-cap strength, but divergent signals—NASDAQ 100 flat while Russell 2000 down—masked extreme single-stock chaos with a 318% spike and multiple biote…

55% Small caps led the day despite the Russell 2000's modest decline, with the broader Russell 2500 and 3000 both outpacing the S&P 500, signaling a rotation away from mega-cap tech into mid and smaller-cap names even as NASDAQ 100 stumbled 0.3%.
30% Biotech and micro-cap volatility dominated the edges: JLHL soared 318%, VRAX doubled on a Fosun supply deal, and FBRX jumped 78% on positive Phase 1b vitiligo data, while AFJK crashed 52% on a terminated business combination and IONS tanked 24% after its Wainua gene-silencing drug failed Phase 3.
15% Five debutants appeared in the gainers list (FBRX, CIRC, LASR, EVGN, CNTB) alongside persistent losers CCHH and TRNR, indicating a market where long-absent names are returning while some laggards continue to slide despite mixed news catalysts like share consolidations and revenue guidance raises.

5 names returned after long absences CCHH · 3-day losers streak TRNR · 3-day losers streak FBRX — first appearance CIRC — first appearance

Market Regime

Thu, Jul 9, 2026 Neutral conf: low macro · prototype

+21

Tailwind −100 … +100 · + tailwind / − headwind

VIX15.8 Drawdown-0.9% Held3d · building SinceJul 7

Top drivers: S&P drawdown (60d) ▲ S&P vs 20d avg ▲ S&P 20d return ▲

processId: history-market-regime

Market Indexes

Thu, Jul 9, 2026 13

S&P 500

7,543.64

+60.41

+0.81%

Dow Jones

52,487.41

+182.17

+0.35%

NASDAQ Composite

26,206.89

+166.86

+0.64%

NASDAQ 100

29,727.10

−82.03

-0.28%

DJ US Total Market

74,817.47

+454.42

+0.61%

Russell 1000

4,111.74

+27.41

+0.67%

S&P MidCap 400

3,781.86

−37.70

-0.99%

Russell 2000

2,992.54

−20.05

-0.67%

Russell 2500

1,267.37

+15.52

+1.24%

Russell 3000

4,295.28

+26.18

+0.61%

Nasdaq Financial-100

7,435.09

+87.59

+1.19%

NIFTY 50

23,962.80

−308.05

-1.27%

VIX

15.84

+0.27

+1.73%

Biggest Gainers

Thu, Jul 9, 2026 50

JLHL

Julong Holding Limited Class A Ordinary SharesIndustrials

$12.79+$9.73

+318.0%

NASDAQ · Mkt cap $152 M

No news headlines were available in the last 48 hours, so the cause of the 318% spike in JLHL cannot be determined from public reporting. The jump likely reflects technical factors, delayed announcements, or market-driven activity without immediate news coverage.

Yahoo Finance returned no headlines for JLHL in the last 48 hours despite a massive single-day gain of 317.97%, making it the top gainer on NASDAQ. This absence of news coverage is striking for such an extreme move. Possible explanations include a delayed earnings release not yet picked up by news aggregators, a corporate action such as a reverse split or restructuring, short squeeze activity if the stock has high short interest or low float, or a rumor circulating on social media or trading platforms not yet formally announced. Without access to the company's investor relations page or SEC filings from the relevant date, it is impossible to confirm which mechanism drove the move. The lack of news does not rule out fundamental catalysts; it simply means they were not captured in the headline feed provided.

VRAX

Virax Biolabs Group LimitedHealthcare

$6.36+$3.18

+100.0%

NASDAQ · Mkt cap $2.5 M

Virax Biolabs announced an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product line and a concurrent $3.3 million capital raise, catalyzing the 100% gain on Thursday.

The stock's doubling was driven by two positive announcements released on the morning of July 9th. The primary catalyst was the exclusive multi-country commercial supply agreement with Fosun Diagnostics, a major Chinese diagnostics company, for the ImmuneSelect product line. This represents meaningful commercial validation and international distribution for Virax's diagnostic products. Secondary support came from the announcement that the company exercised preferred investment options to raise $3.3 million in gross proceeds, demonstrating capital access and reducing near-term funding pressure. For a small-cap biotech company, securing both a marquee distribution partnership and capital simultaneously is typically viewed as sharply positive, justifying the magnitude of the single-day move. The timing suggests both announcements were coordinated for maximum impact.

FBRX

Forte Biosciences, Inc.Healthcare

$36.70+$16.12

+78.3%

TRAX

First Tracks Biotherapeutics IncHealthcare

$32.40+$11.63

+56.0%

NASDAQ · Mkt cap $1.5 B

No news headlines are available in the last 48 hours to explain the 56% jump, so the catalyst remains unclear; the move was likely driven by internal company developments, market rumors, or technical trading activity.

First Tracks Biotherapeutics experienced a substantial 55.99% single-day gain with no corresponding news coverage in the last 48 hours according to the Yahoo Finance RSS feed provided. This disconnect between price action and public headlines suggests either a delayed news pickup by the feed, an after-hours or pre-market announcement not yet reflected in standard news aggregators, or a catalyst unrelated to traditional company news. For a biotherapeutic company of this size, typical catalysts include clinical trial results, regulatory decisions from the FDA, partnership or licensing announcements, or insider transactions. Without confirmed headlines, it is impossible to attribute the move to any specific event. The magnitude of the gain and its ranking as the fourth-largest mover suggest material new information or significant market interest, but the source remains speculative.

CIRC

Circle8 Group, Inc.Healthcare

$0.93+$0.32

+53.4%

WRAP

Wrap Technologies, Inc.Technology

$2.36+$0.77

+48.4%

NASDAQ · Mkt cap $99 M

Wrap Technologies surged 48% on news of a favorable ATF ruling, the launch of WrapShield AI-powered defense platform, and exclusive distribution rights to detection technologies announced over the past two days.

The stock gained on a cluster of positive developments in rapid succession. On July 7-8, Wrap launched WrapShield, an autonomous platform combining threat detection, AI decision support, and operational response capabilities aimed at defense and public safety markets. The same period saw announcement of exclusive distribution rights to unspecified detection technologies. Most directly on July 9, the company highlighted a recent ATF ruling that strengthened its position in the global safety space, though the headline does not detail the specific ruling's nature or impact. These announcements collectively suggest expanded market access, new product capability, and regulatory validation, all of which could justify a meaningful rally in a small-cap stock. However, the headlines lack financial quantification (revenue impact, margins, market size) and specific details of the ATF ruling itself, limiting confidence in the magnitude of the move.

TDTH

Trident Digital Tech Holdings LtdTechnology

$2.59+$0.76

+41.5%

NASDAQ · Mkt cap $2.3 B

Trident Digital Tech announced on July 9 a strategic equity investment in U.S.-based Digital Innovations Group to commercialize an AI-powered IRMA engine across Asia-Pacific and Africa, positioning the company in enterprise AI licensing and SaaS, which likely drove the 41.53% gain.

The July 9 press release explicitly states that Trident Digital Tech has taken a strategic equity stake in Digital Innovations Group to commercialize the AI-powered IRMA Engine across Asia-Pacific and Africa. The announcement emphasizes high-margin, recurring-revenue enterprise AI business opportunities through licensing, SaaS, white-label deployments, and strategic channel partnerships. This positions the company in the rapidly growing generative AI and enterprise software sector, which markets have rewarded strongly in 2026. The timing of the announcement on July 9 aligns precisely with the date of the stock's surge, and the expansion into AI-powered business solutions targeting multiple regions represents a material strategic pivot that investors appear to view as value-accretive. The emphasis on recurring revenue and partnerships suggests a shift toward more predictable, scalable revenue streams.

RPGL

Republic Power Group LimitedTechnology

$2.37+$0.59

+33.1%

NASDAQ · Mkt cap $2.6 M

Republic Power Group regained compliance with Nasdaq's minimum bid price requirement on July 8, lifting the stock 33% the next day as delisting risk was eliminated and investor confidence was restored.

The headline confirms that RPGL regained compliance with Nasdaq's minimum bid price rule, which is a critical threshold for maintaining listing status. Stocks trading below the $1.00 minimum face delisting proceedings, which creates existential uncertainty for shareholders and typically depresses valuations significantly. The company's restoration to compliance directly removes this overhang. A 33% single-day jump following such an announcement is consistent with delisting-risk removal, as it restores the stock to normal operating status and eliminates the legal/regulatory uncertainty that had likely pressured the price downward. This is a structural positive for equity holders rather than a fundamental business improvement, but it is nonetheless material to valuation.

RYOJ

rYojbaba Co., Ltd. Common SharesIndustrials

$3.88+$0.93

+31.5%

NASDAQ · Mkt cap $53 M

No news headlines were published in the last 48 hours for RYOJ, so the 31.53% surge cannot be directly attributed to a disclosed catalyst. The move likely reflects either a technical or sentiment-driven event, delayed news pickup, or market-wide factor not captured in available feeds.

The absence of news coverage within the 48-hour window before this significant gain is notable. While a 31.53% single-day jump is substantial, without access to intraday developments, social media activity, insider trading filings, or broader market context, the specific cause remains unclear. Possible explanations include a corporate announcement not yet reflected in Yahoo Finance's RSS feed, short covering in a thinly-traded stock, technical breakout following accumulated buying pressure, or reaction to sector-wide or market-wide events. Small-cap stocks like RYOJ on NASDAQ often experience outsized moves on limited volume driven by retail interest or momentum rather than fundamental news. Without corroborating headlines or structural insights specific to this company, the actual driver cannot be determined from the evidence provided.

SDOT

Sadot Group Inc.Consumer Defensive

$26.71+$6.40

+31.5%

NASDAQ · Mkt cap $11 M

No news headlines were found in the last 48 hours for SDOT, so the 31.51% gain on July 9 cannot be attributed to a specific announced event; the driver remains unknown without additional context.

The absence of recent news headlines makes it impossible to anchor the explanation to a concrete catalyst such as earnings, a product approval, a partnership, or guidance. A 31.51% single-day move is substantial and typically correlates with material corporate news, a major technical breakdown, or market sentiment shifts. For a smaller-cap or less-liquid stock like SDOT, possible causes include delayed media coverage of an announcement that occurred before the news cycle snapshot, a technical bounce after an oversold condition, short covering if the stock had significant short interest, sector rotation into its industry, or retail investor interest (possibly social media driven). Without headlines or structural knowledge of SDOT's capital structure, float, or short positioning, pinpointing the actual cause is not feasible.

FXHO

UTime LimitedTechnology

$18.70+$4.18

+28.8%

NASDAQ · Mkt cap $54 M

No news headlines were found in the last 48 hours, so the cause of the 28.79% gain cannot be attributed to a disclosed event. The jump likely stems from technical trading, delayed news circulation, or undisclosed corporate developments.

UTime Limited (FXHO) posted a significant single-day gain of 28.79% while ranking among the top 10 gainers on NASDAQ, yet no corresponding news was indexed in the Yahoo Finance RSS feed during the preceding 48 hours. This disconnect between price action and public information flow is notable. The move could reflect several possibilities: (1) a press release issued during market hours that has not yet propagated through major news aggregators, (2) a short squeeze or technical breakout on low volume, (3) an earnings announcement or guidance revision not yet surfaced in the sample, or (4) sector or momentum-driven trading in a micro-cap name. Without direct evidence of a corporate catalyst, we cannot isolate a specific cause. Investors should verify whether company filings, insider transactions, or exchange-listed announcements occurred on or immediately before July 9, 2026.

SRXH

SRX Global Inc.Technology

$2.53+$0.56

+28.4%

LASR

nLIGHT, Inc.Technology

$74.71+$16.03

+27.3%

RNAZ

TransCode Therapeutics, Inc.Healthcare

$9.60+$1.72

+21.8%

NASDAQ · Mkt cap $3.4 M

No news headlines were found in the last 48 hours, so the 21.84% gain on RNAZ cannot be directly attributed to a specific announced catalyst. The move is likely driven by technical factors, rumors, or delayed news dissemination.

TransCode Therapeutics is a small-cap biotech company, a category that frequently experiences sharp intraday moves on minimal or delayed news flow. The absence of Yahoo Finance headlines does not rule out that news exists elsewhere or that the market is reacting to something announced outside the standard RSS feed window. Alternatively, the move could reflect technical buying pressure, short covering, or retail momentum in a thinly traded name. Biotech stocks often gap on clinical trial results, partnership announcements, or regulatory updates that may take time to propagate through aggregators. Without confirmed headlines directly tied to RNAZ, any explanation remains speculative.

SUNE

SUNation Energy Inc.Technology

$2.56+$0.45

+21.3%

NASDAQ · Mkt cap $9.2 M

No news headlines were found in the last 48 hours for SUNE, so the 21.33% gain cannot be directly attributed to a specific company announcement or market-moving event based on available information.

The absence of recent news headlines makes it difficult to pinpoint a concrete catalyst for SUNation Energy's sharp 21.33% intraday gain. Solar and renewable energy stocks can be sensitive to several types of catalysts: sector rotation into clean energy amid shifting energy policy discussions, short covering or retail interest in a lower-priced name, updates on residential solar installation pipelines, changes in financing availability, or broader market sentiment shifts favoring renewable companies. Without corroborating headlines or earnings releases, it is also possible that the move reflects a delayed market reaction to news not yet indexed by the RSS feed, technical support level holding, or even an error in data reporting. For a micro-cap or lower-liquidity name like SUNE trading under three dollars, volume spikes can amplify percentage moves even on modest absolute share purchases.

JBDI

JBDI Holdings LimitedConsumer Cyclical

$1.37+$0.24

+21.2%

NASDAQ · Mkt cap $12 M

No news was published about JBDI in the last 48 hours, so the 21% gain on July 9 lacks an identifiable headline catalyst. The move likely reflects technical trading, short covering, or untracked corporate developments.

The absence of any recent news headlines in the provided feed creates significant uncertainty about the driver of this substantial single-day gain. JBDI Holdings Limited is a relatively small-cap NASDAQ-listed company, and stocks in this category can be sensitive to technical factors such as short-squeeze dynamics, options expiration effects, or algorithmic momentum trading. Alternatively, the catalyst could be a legitimate corporate development—earnings results, guidance updates, strategic announcements, or institutional activity—that simply did not appear in Yahoo Finance's RSS feed within the 48-hour window. Without access to the company's investor relations announcements, SEC filings, or other news sources, it is not possible to isolate a specific event. The jump to rank 16 among daily gainers suggests either broad positive sentiment among retail traders or a targeted move in a low-volume name.

Jianzhi Education Technology Group Company LimitedTechnology

$3.87+$0.67

+20.9%

NASDAQ · Mkt cap $4.1 M

No news headlines were found in the last 48 hours, so the 20.94% gain in JZ stock cannot be attributed to any reported event or announcement. The jump likely reflects technical trading, market speculation, or delayed news not yet captured in the RSS feed.

The absence of recent news headlines makes it impossible to identify a specific catalyst for this significant single-day gain. JZ is a Chinese education technology company, and stocks in this sector can experience sharp moves based on regulatory developments, enrollment announcements, financial results, or shifts in investor sentiment toward the EdTech space. Educational technology stocks have historically been volatile, particularly those with China exposure. Possible explanations include: first, a delayed or untracked earnings release or guidance update that has not yet surfaced in the headline feed; second, short covering or technical momentum in a stock that may have accumulated put options or short positions. Without corresponding news, neither hypothesis can be confirmed. The 20.94% move is substantial and rank 17 on the daily gainers list suggests real volume and interest, but the cause remains opaque from the available evidence.

EVGN

Evogene Ltd.Healthcare

$0.50+$0.09

+20.7%

NASDAQ · Mkt cap $9.5 M

Evogene announced a joint drug discovery initiative with Tel Aviv University's Blavatnik Center, leveraging its ChemPass AI platform for small-molecule discovery. The partnership appears to have sparked investor optimism about the company's AI-driven pharmaceutical applications.

The two news items describe the same announcement made on July 8-9, 2026: Evogene is partnering with Tel Aviv University's Blavatnik Center for Drug Discovery to combine its proprietary ChemPass AI platform with the university's laboratory infrastructure. This represents a validation of Evogene's computational chemistry technology through collaboration with an established academic drug discovery center. For a micro-cap biotech company trading at $0.50, such partnerships are typically viewed positively as they reduce R&D burden, provide credibility, and open pathways to pharmaceutical development. The 20.74% single-day gain suggests investors interpreted this as material progress for a computational chemistry company that likely has faced skepticism about its technology's real-world applicability. The timing and ranking among top gainers indicates this news drove meaningful retail or institutional interest.

ZSQR

Coeptis Therapeutics Holdings, Inc.Technology

$8.49+$1.45

+20.6%

NASDAQ · Mkt cap $218 M

No news headlines were reported in the last 48 hours for ZSQR, so the 20.6% gain cannot be attributed to a specific announced catalyst. The move likely reflects either a delayed market reaction to older news, technical trading, or an untracked event.

The absence of recent news headlines in Yahoo Finance's RSS feed for ZSQR over the past 48 hours presents a significant gap between the stock's strong performance and documented public information. Coeptis Therapeutics is a clinical-stage biopharmaceutical company, and moves of this magnitude in such stocks typically correspond to clinical trial results, regulatory decisions, financing announcements, or partnership news. Without access to the triggering event, reasonable hypotheses include: first, a delayed or uncovered announcement from biotech news wires not yet indexed by Yahoo Finance at the time of snapshot; second, short covering or technical momentum in a thinly traded small-cap name; or third, news announced late on July 9 that had not yet propagated to the RSS feed used here. The lack of accompanying headlines makes it impossible to distinguish between these scenarios with confidence.

OPEG

LEVERAGE SHARES 2X LONG OPEN DAILY ETF

$5.66+$0.96

+20.4%

NASDAQ

No news headlines were found in the last 48 hours, but the 20.39% gain is consistent with OPEG being a 2x leveraged long ETF that amplifies daily moves in its underlying asset, likely reflecting a strong rally in open-end fund or related indices.

OPEG is a 2x leveraged daily ETF, meaning it is designed to deliver twice the daily return of its underlying index or benchmark. With no news headlines identified in the provided 48-hour window, the gain cannot be attributed to a specific corporate event, earnings announcement, regulatory action, or market-moving disclosure about the underlying holdings. However, this type of security is structurally engineered to magnify intraday or daily price movements. A 20.39% one-day jump in a 2x leveraged product implies roughly a 10% move in the underlying benchmark or index. This could reflect broad market strength, a sector-specific rally, rebalancing activity, or technical buying pressure in the leveraged ETF space itself. Without access to the underlying index performance or intraday catalysts, the precise driver remains unclear.

CNTB

Connect Biopharma Holdings LimitedHealthcare

$2.66+$0.44

+19.8%

NASDAQ · Mkt cap $155 M

No news headlines were found in the last 48 hours, so the 19.82% gain on CNTB cannot be attributed to a disclosed catalyst. The move likely reflects delayed news coverage, technical trading, or an undisclosed announcement.

The absence of any headline from Yahoo Finance in the 48 hours preceding this strong single-day move creates ambiguity about the driver. For a small-cap biotech like Connect Biopharma, typical catalysts include clinical trial data releases, regulatory filings, partnership announcements, or changes in analyst coverage. It is possible that material news was released but has not yet appeared in the RSS feed examined, or that the move was driven by technical factors such as short covering, options expiration, or accumulation by institutional buyers. Without access to real-time news feeds or company disclosures beyond the snapshot provided, we cannot identify a specific event as the cause.

SNWV

SANUWAVE Health Inc.Healthcare

$12.10+$2.00

+19.8%

NASDAQ · Mkt cap $44 M

No news headlines were found in the last 48 hours, so the 19.75% gain cannot be attributed to any identified public announcement or event. The jump likely stems from technical factors, delayed news digestion, or undisclosed catalyst.

SNWV rose nearly 20% on July 9, 2026, but no recent headlines explain the move. For a small-cap medical device company like SANUWAVE Health, daily swings of this magnitude without identified news often reflect a few typical scenarios: technical short covering or a squeeze on a thinly traded float, delayed market reaction to older news not yet indexed by the RSS feed, retail or institutional accumulation ahead of expected catalysts, or a rumor not yet reflected in major financial headlines. The lack of contemporaneous news makes it impossible to distinguish between these possibilities. Healthcare microcaps are particularly prone to sharp moves on low volume and thin liquidity, which could explain the magnitude alone. Without access to insider filings, options activity, or short interest data, attributing this move to a specific cause would be speculation.

MRAL

GraniteShares 2x Long MARA Daily ETF

$62.31+$10.25

+19.7%

NASDAQ

No news headlines were found in the last 48 hours, but MRAL is a 2x leveraged long ETF tracking Mara (Marathon Digital), so a ~10% move in the underlying stock would mechanically amplify to roughly a 19-20% move in the ETF, explaining the gain.

The absence of recent news headlines means we cannot identify a specific catalyst from published sources. However, MRAL's structural nature as a 2x daily leveraged long ETF is highly relevant here. These products are designed to deliver twice the daily return of their underlying index or stock. If Marathon Digital (MARA) gained approximately 9-10% on July 9th due to any factor—whether crypto market strength, company-specific news about Bitcoin holdings or mining operations, short covering, or technical momentum—the 2x leverage would mechanically double that move to roughly 19-20%, matching the observed +19.68% move in MRAL. Without news on Marathon itself, the most likely categories are crypto market tailwinds, mining-sector strength, or Bitcoin price appreciation.

XCH

XCHG Limited American Depositary ShareIndustrials

$0.77+$0.13

+19.7%

NASDAQ · Mkt cap $21 M

No news headlines were found in the last 48 hours, so the 19.65% gain likely reflects technical trading, delayed announcement pickup, or market rumors that are not yet visible in major news feeds.

XCH traded up nearly 20% on 2026-07-09 with no corresponding headlines in the Yahoo Finance RSS feed from the prior 48 hours. This disconnect suggests the catalyst either occurred before the snapshot window, remains unconfirmed in mainstream outlets, or is driven by technical factors such as short covering, options expiration mechanics, or retail trading momentum. Thinly traded ADRs like XCHG Limited can experience outsized percentage moves on modest volume shifts. Without access to social media, press releases, or non-English news channels, the specific driver remains opaque. Possible categories include a delayed earnings report, a corporate action announcement, international news not yet picked up by US feeds, or pure technical reversal from oversold conditions.

PTLE

PTL LimitedConsumer Cyclical

$9.29+$1.49

+19.1%

NASDAQ · Mkt cap $50 M

No news headlines were found in the last 48 hours, so the 19.10% gain on July 9th likely stems from technical trading, delayed news pickup, or market rumors not yet reflected in major financial feeds.

PTL Limited jumped 19.10% to rank among the day's top 25 gainers, yet no recent news was published to Yahoo Finance in the prior 48 hours. This disconnect suggests the catalyst either occurred before the 48-hour window, was announced through a channel not indexed by Yahoo Finance feeds, or reflects technical factors such as short covering, options-related hedging flows, or momentum buying. Without access to company press releases, SEC filings, earnings reports, or sector-specific developments, identifying the precise trigger is not possible. The absence of headline coverage combined with a strong single-day move is consistent with either a delayed market reaction to older news or a liquidity-driven repricing unrelated to fundamental information.

ARMG

Leverage Shares 2x Long ARM Daily ETF

$32.91+$5.13

+18.5%

NASDAQ

No news headlines were found in the last 48 hours, but the 18.47% gain is consistent with ARMG's 2x leverage structure amplifying a significant rally in the underlying ARM Holdings stock price.

ARMG is a leveraged ETF that aims to deliver twice the daily return of ARM Holdings, the chip design company. With no news provided in the last 48 hours, the 18.47% jump most likely reflects ARM Holdings itself gaining roughly 9% or more on the day. ARMG moves are mechanically driven by its underlying asset's price action, so the substantial daily move points to either a strong performance day for ARM stock more broadly (possibly sector momentum in semiconductor design) or a delayed market reaction to earlier news about ARM, earnings, guidance, or product announcements. Without access to ARM-specific headlines or price data, we cannot identify the specific catalyst, but leverage amplification is the structural explanation for why this ETF significantly outperformed on a given day.

OSTX

OS Therapies IncorporatedHealthcare

$1.72+$0.26

+17.8%

AMEX · Mkt cap $66 M

OS Therapies announced it accepted a new FDA meeting request to review biomarker data as part of the BEST Program, with a CDER meeting expected in summer 2026, likely driving the 17.81% gain in a small-cap biotech stock responsive to regulatory progress.

The headline establishes that OS Therapies received formal FDA acknowledgment of a meeting request focused on biomarker data review under the BEST (Biomarker, Performance, and Molecular Targets) Program. This represents regulatory engagement on a potentially important pathway question. For early-stage or clinical-stage biotech firms, FDA meeting approvals are typically viewed as validation that the agency is willing to engage constructively on the company's strategy. The parallel mention of a Type B Statistical Methods Meeting with CBER adds specificity to the regulatory dialogue. Small-cap biotech stocks are particularly sensitive to FDA interactions because they signal de-risking of development programs and can improve the perceived probability of eventual approval. A 17.81% single-day move is consistent with this class of stock responding to positive regulatory signals.

ONTX

Onconova Therapeutics, Inc.Financial Services

$23.40+$3.51

+17.6%

RVNL

GraniteShares 2x Long RIVN Daily ETF

$33.66+$4.95

+17.2%

NASDAQ

No news headlines were found in the last 48 hours, but RVNL is a 2x leveraged ETF tracking Rivian stock, so a strong rally in the underlying RIVN would mechanically amplify into a larger percentage gain on this derivative product.

The absence of news in the provided headline feed makes direct causation impossible to establish from the evidence given. However, RVNL's structure as a 2x long daily leveraged ETF targeting Rivian (RIVN) provides a clear mechanical explanation for outsized moves. If Rivian stock itself rose approximately 8–9% on July 9, 2026, the 2x daily leverage would produce a gain in the 16–18% range, consistent with RVNL's reported +17.25% move. This does not identify what moved Rivian itself—that could be positive earnings, positive industry news, shorts covering, momentum trading, or any other catalyst affecting the underlying stock—but it explains why a leveraged derivative would show amplified price action. To identify the root cause, one would need to research Rivian's own headlines and trading on that date.

ISPR

Ispire Technology Inc.Consumer Defensive

$1.51+$0.22

+17.1%

NASDAQ · Mkt cap $86 M

No news headlines were found in the last 48 hours, so the +17.05% jump likely reflects technical trading, short covering, or an announcement not yet indexed by the financial news feed.

Ispire Technology is a small-cap NASDAQ stock, and the absence of recent news headlines does not rule out a catalyst. The 17 percent single-day gain could stem from several sources: a press release or corporate announcement made but not yet picked up by major financial news aggregators, short-squeeze activity typical of lower-priced stocks with modest float, positive sentiment from social media or retail trading communities, or sector-wide momentum in vaping or cannabis-adjacent hardware. Alternatively, the move could reflect technical factors such as a break above a key resistance level or rebalancing activity. Without a concrete news headline linking to the stock or the company, attribution remains speculative.

SVAC

Spring Valley Acquisition Corp. III Class A Ordinary SharesFinancial Services

$9.24+$1.34

+17.0%

NASDAQ · Mkt cap $337 M

No news headlines were found in the last 48 hours to explain the 16.96% jump in SVAC, suggesting the move may be driven by SPAC-related trading activity, merger speculation, or technical factors rather than a confirmed corporate announcement.

Spring Valley Acquisition Corp. III is a special purpose acquisition company (SPAC), which are blank-check entities formed to acquire private companies and take them public. The absence of any recent news headlines does not rule out a catalyst; SPAC price movements are often driven by closed-door merger negotiations, leaks, or insider accumulation that may precede formal announcements. Additionally, SPAC Class A shares can experience momentum trading based on redemption dynamics, merger probability shifts, or sector-wide sentiment changes. The 16.96% gain on no identified headline suggests either an event that has not yet reached major news wires, technical momentum buying, or market positioning ahead of an anticipated announcement. Without confirmed headlines, the precise driver remains unknown.

AGRZ

Agroz Inc. Ordinary SharesConsumer Defensive

$0.43+$0.06

+17.0%

NASDAQ · Mkt cap $6.9 M

No news headlines were found in the last 48 hours, so the 16.95% gain on AGRZ cannot be tied to a specific corporate announcement or market event.

The absence of recent news headlines makes it impossible to identify a concrete catalyst for today's 16.95% jump in AGRZ stock price. Given that AGRZ trades on NASDAQ at a very low price point of $0.43, this type of micro-cap or penny stock is typically subject to outsized volatility driven by factors other than fundamental news. Common drivers for such moves in this category include technical momentum, retail trading activity, short covering if the stock had a significant short position, or unindexed corporate developments that may not yet be widely covered by financial news aggregators. Without access to SEC filings, social media discussion, or real-time trading data, determining the specific cause remains speculative.

FTH

Faeth Therapeutics, Inc.Healthcare

$32.54+$4.52

+16.1%

NASDAQ · Mkt cap $1.0 B

No news headlines were found in the last 48 hours for FTH, so the 16.13% gain lacks an identifiable catalyst in the available information. The move could reflect delayed market reaction to an earlier announcement, insider activity, technical momentum, or sector-wide activity.

The absence of recent news headlines makes it impossible to point to a specific catalyst such as an earnings beat, clinical trial result, FDA approval, partnership announcement, or guidance change. For a biotech or therapeutics company like Faeth, typical catalysts for large single-day gains include positive Phase trial data, regulatory decisions, licensing deals, or management changes. Without access to news from earlier in the week, social media activity, insider transactions, or knowledge of broader sector trends on July 9, 2026, we cannot determine whether the move reflects a delayed market reaction to a pre-announced event, a rumor, short covering, or pure technical momentum. The stock's rank as 33 biggest gainer suggests it moved in concert with sector strength rather than in isolation, but that remains inference.

ONCY

Oncolytics Biotech Inc.Healthcare

$0.92+$0.13

+16.1%

NASDAQ · Mkt cap $106 M

No news headlines were found in the last 48 hours, so the 16% gain on ONCY is likely driven by technical trading, sector momentum, or an untracked catalyst such as a clinical update or institutional positioning.

Oncolytics Biotech is a small-cap biotech stock trading at $0.92, making it sensitive to momentum trading and technical moves even on modest volume. The absence of news in the Yahoo Finance RSS feed does not rule out a genuine catalyst; clinical-stage biotech companies often experience sharp moves on clinical trial updates, regulatory feedback, partnership news, or shifts in sentiment around their pipeline assets. Given ONCY's historical focus on oncolytic virus therapeutics, the move could reflect positive interim data, a licensing deal, or analyst commentary not yet captured in major headlines. Alternatively, the jump could be a technical rebound in a beaten-down stock, short-covering, or sector-wide positive sentiment toward smaller biotech names. Without confirmed news, all of these remain hypotheses rather than established facts.

FRVO

Fervo Energy Co.Utilities

$27.35+$3.78

+16.0%

NASDAQ · Mkt cap $5.1 B

Fervo Energy surged 16% on news that its third-generation well design achieved a 143% increase in drilling rates, with the Sawtooth 7 well setting a new speed record, demonstrating significant operational progress in enhanced geothermal systems technology.

The headline reports a concrete operational milestone: Fervo's latest well design has accelerated drilling performance substantially, completing a 7,500-foot lateral in 21 days and reaching 19,448 feet measured depth. This represents measurable engineering progress that directly addresses drilling efficiency, a key cost and timeline driver for geothermal development. For a capital-intensive, pre-revenue or early-revenue geothermal company, tangible evidence of learning curve improvements and faster drilling execution is material to investor confidence in unit economics and project scalability. The 143% improvement figure is quantified and attributed to the company's own disclosed operational data, making this a genuine positive signal rather than speculative news. Geothermal stocks are particularly sensitive to technical validation because the technology is still emerging and cost per megawatt installed remains a competitive metric.

SPCB

SuperCom Ltd.Industrials

$11.94+$1.65

+16.0%

NASDAQ · Mkt cap $68 M

SuperCom announced it secured a new electronic monitoring contract with a Georgia-based provider, fully displacing an incumbent competitor, which likely triggered the 16% gain as a material new revenue win.

The headline published on 2026-07-09 at 13:09 UTC describes SuperCom winning a contract with an established Georgia-based electronic monitoring service provider and explicitly states it is "fully displacing the incumbent." This is a concrete business development win that directly expands the company's addressable market in the EM sector. The timing of the announcement (morning US time) and the stock's ranking as the 36th biggest gainer suggest the market responded positively to proof of execution and competitive displacement. The announcement provides measurable evidence that SuperCom can win against entrenched competitors, which reduces business uncertainty and justifies a sharp intraday move for a smaller-cap provider in the IoT and e-Government space. No financial terms were disclosed in the snippet provided, but the mere fact of a new contract win and incumbent displacement is sufficient to drive investor optimism.

PEPG

PepGen Inc.Healthcare

$2.30+$0.32

+15.9%

NASDAQ · Mkt cap $201 M

No news headlines were found in the last 48 hours to explain PepGen's 15.87% gain, so the catalyst remains unclear; a biotech stock of this size might have moved on clinical trial results, partnership news, or analyst coverage that was not captured in the provided feeds.

PepGen Inc. (PEPG) jumped nearly 16% on July 9, 2026, but no news articles appeared in the Yahoo Finance RSS feed during the preceding 48 hours. This absence of reported news is notable. For a small-cap biotech company like PepGen, typical catalysts include positive clinical trial data announcements, FDA decisions, partnership or licensing deals, analyst initiations, or insider buying. The lack of headline coverage could mean the catalyst arrived outside the monitored news window, was not yet widely syndicated at snapshot time, or came from a non-traditional source such as a direct company announcement, social media discussion, or short-covering. Without access to company filings, clinical trial databases, or real-time social sentiment data, pinpointing the specific driver is not possible from the evidence provided here.

RBNE

Robin Energy Ltd.Energy

$8.03+$1.10

+15.9%

NASDAQ · Mkt cap $1.5 M

No news headlines appeared in the last 48 hours to explain the 15.86% jump on July 9, 2026. The catalyst remains unclear without additional context on company announcements or market developments.

The absence of recent news headlines makes it difficult to pinpoint a specific catalyst for RBNE's strong gain. A 15.86% single-day move in a stock typically reflects a material event such as earnings results, guidance revision, regulatory approval, partnership announcement, or significant insider buying. Given that Robin Energy Ltd. operates in the renewable or clean energy sector based on its name, possible drivers could include project milestones, policy changes favorable to the energy transition, or debt restructuring. However, these remain hypotheses rather than confirmed causes. It is also possible the move reflects technical factors such as covering of short positions, algorithmic rebalancing, or delayed market reaction to a prior announcement not captured in the 48-hour window provided.

GRAN

Grande Group Limited Class A Ordinary SharesFinancial Services

$1.48+$0.20

+15.6%

NASDAQ · Mkt cap $31 M

No news headlines were found in the last 48 hours explaining Grande Group's 15.62% gain, so the driver remains unclear; likely candidates include technical bounces, delayed announcements, or market sentiment shifts in the small-cap space.

Yahoo Finance returned no headlines for Grande Group Limited in the past 48 hours, which is the most relevant window for explaining an intraday mover. A +15.62% jump on a low-priced stock like GRAN ($1.48) can be driven by several categories: delayed earnings or guidance announcements not yet indexed in headline feeds, short covering or momentum-driven technical bounces common in small-cap and penny-stock ranges, insider buying signals, sector rotation favoring whatever industry GRAN operates in, or simply low liquidity amplifying normal volume swings. Without news data or knowledge of GRAN's business sector, recent earnings history, or short float status, substantive attribution is not possible. The absence of news headlines itself is notable and suggests either a non-fundamental catalyst or a lag in news distribution to the feed.

GIXXR

GigCapital9 Corp. Rights

$0.30+$0.04

+15.4%

NASDAQ

No news headlines appeared in the last 48 hours, but GIXXR is a SPAC rights offering that typically moves on redemption dynamics, warrant arbitrage, or parent company developments rather than company-specific fundamentals.

GIXXR trades as the rights component of GigCapital9 Corp., a blank-check acquisition vehicle. These rights-only instruments are extremely illiquid and volatile, often experiencing sharp moves on minimal volume driven by redemption mechanics, warrant spread adjustments, or news about the parent SPAC's merger negotiations or timeline. Without published headlines in the search results, the 15.38% gain likely reflects one or more of the following: a shift in the valuation of the associated warrants or common shares, technical trading in thin markets, a delayed announcement not yet indexed by the news feed, or activity related to the parent company's acquisition target discussions. SPAC rights are particularly susceptible to small catalysts because of their structural leverage and tiny float.

NDRA

ENDRA Life Sciences Inc.Healthcare

$5.49+$0.73

+15.3%

NASDAQ · Mkt cap $5.7 M

No news headlines were found in the last 48 hours, so the 15.34% gain on NDRA cannot be tied to a specific announced event. The move likely reflects either a delayed market reaction, technical momentum, or an unindexed catalyst.

Yahoo Finance returned zero headlines for ENDRA Life Sciences in the 48-hour window covering this gain. Without announced earnings, FDA decisions, clinical trial results, partnership news, or guidance changes on the record, the cause remains unconfirmed. ENDRA is a small-cap medical device and life sciences company, the type that can experience sharp moves on insider buying, short covering, research coverage initiation, clinical data dissemination via investor relations channels not yet indexed by major news aggregators, or pure technical momentum in a lower-liquidity stock. The 15.34% single-day jump is material but not unprecedented for this sector and market-cap range. Without corroborating headlines, however, any specific explanation would be speculation.

UBXG

U-BX Technology Ltd.Communication Services

$4.63+$0.61

+15.2%

NASDAQ · Mkt cap $11 M

No relevant news headlines were found in the last 48 hours, so the 15.17% gain on UBXG likely reflects a technical bounce, delayed disclosure lag, or market rumor unconfirmed by Yahoo Finance's feed.

The absence of any news headlines in the 48-hour window preceding this significant 15.17% rally makes it difficult to pin down a specific catalyst with confidence. UBXG is a small-cap technology stock trading at $4.63, which may explain why news flow is sparse or delayed relative to price movement. Small-cap stocks are particularly prone to technical bounces, short covering, or social media-driven momentum unaccompanied by formal news releases. It's also possible that material news broke via press release or company channels but has not yet been indexed by Yahoo Finance's RSS feed, or that the move reflects a market reaction to an announcement from a competitor, industry data, or macro shift affecting the sector. Without headlines or structural knowledge of this specific security, however, attribution remains speculative.

GIBO

GIBO Holdings LimitedCommunication Services

$28.78+$3.78

+15.1%

NASDAQ · Mkt cap $79 M

No news headlines were found in the last 48 hours, so the 15.12% gain cannot be attributed to a specific disclosed event. The move likely reflects technical buying, delayed news pickup, or market sentiment unrelated to public announcements.

The absence of any headlines in the last 48 hours makes it impossible to point to a specific catalyst such as earnings, product announcements, regulatory approvals, or strategic transactions. A 15% single-day move is substantial and typically warrants public disclosure or media coverage if driven by company-specific fundamentals. Without additional context about GIBO Holdings' business model, recent performance, analyst coverage, or market positioning, the most plausible explanations fall into broad categories: the move could reflect technical momentum or algorithmic buying, a delayed reaction to news released before the 48-hour window, institutional accumulation ahead of an upcoming event, sector rotation into the stock's industry, or retail interest driven by social media or other non-traditional signals. It is also possible that relevant news exists but was not captured by the Yahoo Finance RSS feed provided.

BBIO

BridgeBio Pharma, Inc.Healthcare

$90.17+$11.84

+15.1%

NASDAQ · Mkt cap $15 B

BridgeBio surged 15% after rival AstraZeneca and Ionis announced their late-stage gene-silencing drug Wainua failed its Phase 3 trial, removing competitive pressure in the rare disease space where BBIO operates.

The news establishes that AstraZeneca and Ionis's CARDIO-TTRansform trial for eplontersen (Wainua) missed its primary endpoint on July 9, causing AstraZeneca to crash 6% and Ionis to decline. BofA characterized the failure as a surprise. BridgeBio's 16% gain (matching the observed 15% move) appears directly tied to this competitive setback for a rival gene-silencing therapy. BBIO benefits from reduced competition in a space where it operates with Attruby and a pipeline of late-stage candidates. Recent articles from July 8 focus on BBIO's Attruby launch momentum and multiple upcoming catalysts, but those positive developments alone do not explain the timing or magnitude of the July 9 surge. The trial failure for a competitor in the same therapeutic space is the most plausible near-term catalyst, removing a material competitive threat and potentially improving BBIO's commercial outlook in rare disease markets.

TXG

10x Genomics, Inc.Healthcare

$43.10+$5.63

+15.0%

NASDAQ · Mkt cap $8.2 B

10x Genomics surged 15% after beating Q1 earnings estimates on both revenue and EPS, drawing renewed investor interest in the stock despite ongoing valuation debates.

The headlines establish that 10x Genomics reported quarterly results that topped analyst forecasts for both revenue and earnings per share on 2026-07-09. This earnings beat is the most concrete catalyst tied to the stock's 15% intraday jump and its ranking as the 45th biggest gainer. The same day's coverage also reflects investors reassessing the stock following this beat, with multiple articles examining valuation metrics (DCF analysis, sales multiples, cash flow ratios) and noting the stock has already surged 209.7% over the past year. The company was also referenced in relation to index changes, though details are truncated. While some articles raise concerns about whether the stock is now overvalued post-earnings, the beat itself—a direct miss-to-beat event—is a standard trigger for single-day momentum in growth stocks. This appears to be a straightforward positive earnings surprise catalyst rather than a fundamental shift in the business.

MagnaChip SemiconductorTechnology

$4.23+$0.55

+14.9%

NYSE · Mkt cap $122 M

No material news catalyst was published today. The 14.95% jump on MX likely reflects technical momentum, short covering, or sector-wide semiconductor strength, with earnings results not due until July 29.

The only headline from the past 48 hours is a routine announcement that Magnachip will report Q2 2026 results on July 29, 2026—a forward-looking statement with no actual financial data or guidance. This type of earnings calendar disclosure typically does not drive a single-day 15% move. The timing suggests the stock may have responded to broader semiconductor sector momentum, short-squeeze dynamics given MX's historically volatile trading, or technical factors such as a break above resistance levels. Without access to intraday volume data, market-wide semiconductor trends, or insider transactions, the specific catalyst remains unclear. The upcoming earnings date may be creating anticipatory positioning ahead of the July 29 report.

UIS

Unisys CorporationTechnology

$4.08+$0.52

+14.6%

NYSE · Mkt cap $201 M

The 14.61% gain does not appear to be directly driven by the two recent headlines, which cover a student innovation competition and a routine earnings date announcement. The move likely reflects either positive guidance expectations ahead of the Q2 earnings call on July 29 or a broader market or …

Neither of the two headlines provided establishes a concrete catalyst for the move. The July 9 announcement about the 17th Unisys Innovation Program is a routine corporate social responsibility update with no financial implications. The July 8 announcement merely sets the earnings release date for July 29, providing no preview of results or guidance. A 14.61% single-day jump in a stock ranked 47 among gainers typically requires material news—a contract win, earnings guidance, strategic announcement, or sector tailwind. Without such news in the provided headlines, we must infer the driver: either market participants are positioning ahead of the Q2 earnings reveal (betting on positive results), the stock responded to market-wide sentiment or technical factors, or news material to UIS moved through channels not captured in this feed.

LRMR

Larimar Therapeutics, Inc.Healthcare

$4.13+$0.52

+14.4%

NASDAQ · Mkt cap $442 M

A director's purchase of approximately 167,000 shares at $3.33–$3.35 per share signaled insider confidence, likely triggering the 14.4% intraday gain as retail and momentum traders interpreted the buying as a bullish vote.

The only headline provided reports insider buying by a company director across multiple transactions totaling roughly $167,000. This type of open-market purchase by a director is often viewed as a positive signal of management's conviction in the stock's value, especially when executed at prices well below the current trading level. The timing of the news—released after hours on July 8—aligns with the stock's jump on July 9. However, insider buying alone does not typically drive a 14% single-day move unless the stock was already technically oversold or momentum-dependent. Without additional context on volume, short interest, or other catalysts released in parallel, it is reasonable to infer that the insider purchase was the headline news that triggered buying, but we cannot rule out coincident technical factors or broader sector sentiment shifts that may have contributed equally to the move.

CTNT

Cheetah Net Supply Chain Service Inc.Industrials

$1.86+$0.23

+14.1%

NASDAQ · Mkt cap $5.0 M

No headlines were found in the last 48 hours to explain CTNT's 14.11% gain, making this move difficult to attribute to a specific catalyst based on available information.

The absence of recent news headlines for Cheetah Net Supply Chain Service Inc. means the move cannot be tied to a named earnings beat, contract award, guidance change, or other announced corporate event. Small-cap and micro-cap stocks trading on NASDAQ frequently experience sharp intraday moves driven by factors outside traditional news: technical bounces from oversold levels, short covering, retail trading activity, sector rotation, or delayed news dissemination from less-covered issuers. Given CTNT's trading price near $1.86, this appears to be a lower-priced equity that may attract momentum or speculative trading. Without verifiable news or a known structural catalyst, the driver of this 14.11% move remains unconfirmed, though technical relief and retail interest are plausible hypotheses for micro-cap movers.

BTDR

Bitdeer Technologies GroupTechnology

$14.33+$1.77

+14.1%

NASDAQ · Mkt cap $2.6 B

Bitdeer announced a $36 million Nevada manufacturing facility to produce SEALMINER hardware units, expanding its AI and Bitcoin mining footprint domestically, which drove the 14% gain on 2026-07-09.

The headlines establish that Bitdeer broke ground on a $36 million advanced electronics manufacturing plant in Nevada intended to produce thousands of computing hardware units monthly for its AI and Bitcoin mining operations. This represents a concrete capital deployment and domestic infrastructure expansion in the high-growth AI and cryptocurrency hardware sectors. The timing of multiple news outlets covering this announcement on the same day, combined with Cramer's mention of AI infrastructure peers, suggests positive sentiment around the sector broadly. The stock's 14.09% jump aligns logically with investor enthusiasm for a major capacity expansion that signals management confidence and positions the company to scale production domestically rather than relying solely on offshore manufacturing.

Biggest Losers

Thu, Jul 9, 2026 50

AFJK

Aimei Health Technology Co., LtdFinancial Services

$12.89−$13.80

-51.7%

NASDAQ · Mkt cap $39 M

Aimei Health Technology announced the termination of its business combination agreement with United Hydrogen Group on July 8, a major corporate event that triggered the 51.7% single-day collapse in AFJK stock price.

The headline explicitly documents that Aimei Health Technology terminated a business combination agreement with United Hydrogen Group, announced on July 8, 2026. This is a material corporate event. A termination of a planned merger or business combination typically represents a significant strategic setback for shareholders, destroying expected synergies, deal value, or a planned pivot to a new business line. For a NASDAQ-listed company, such an announcement would be expected to cause substantial selling pressure. The lack of detail in the truncated headline prevents confirmation of why the deal was terminated (mutual agreement, breach, regulatory failure, financing collapse, or other cause), but the termination itself is the clear catalyst. The magnitude of the decline—over 51 percent in a single day—is consistent with a major strategic disappointment or loss of a transformative transaction that investors were pricing in.

BYRN

Byrna Technologies Inc.Industrials

$3.94−$2.00

-33.7%

NASDAQ · Mkt cap $89 M

Byrna Technologies crashed 33.67% after reporting Q2 2026 earnings that badly missed expectations, with revenue down 42.5% year-over-year and a loss of $0.44 per share versus analyst forecasts, driven by weak e-commerce traffic and lower conversion rates.

The earnings miss was severe and multifaceted. Byrna reported Q2 revenue of $16.39 million, down 42.5% year-over-year and missing Wall Street estimates by 28.46%. The company posted a GAAP loss of $0.44 per share, representing a 340% negative earnings surprise versus consensus. Management attributed the collapse to weaker e-commerce traffic, lower conversion rates, and slower retail reorders. While Byrna announced a strategic acquisition of HERO Defense Systems assets on July 8, intended to expand its product portfolio into lower-priced everyday-carry items, this forward-looking development was overshadowed by the stark operational deterioration revealed in the earnings report. Management acknowledged the challenges but offered only vague references to "tactical changes and new market strategies" without concrete recovery metrics, leaving investors with little confidence in near-term stabilization.

RXT

Rackspace Technology, Inc.Technology

$4.37−$2.21

-33.6%

NASDAQ · Mkt cap $839 M

Rackspace slashed its full-year 2026 revenue guidance by $150 million and announced a $250 million stock offering to fund AI expansion, causing a massive 33.59% sell-off despite announcing a strategic partnership with Palantir.

On July 9, 2026, Rackspace Technology reported preliminary Q2 results showing a wider-than-expected adjusted loss and significantly reduced its fiscal 2026 revenue and EBITDA outlook. The company simultaneously announced a $250 million equity offering to fund its enterprise AI growth strategy and unveiled a preferred partnership with Palantir for deploying Foundry and AIP in regulated markets. While the Palantir partnership and AI acceleration plans were positioned as positive strategic moves, the magnitude of the guidance cut and the capital raise via stock offering overwhelmed sentiment. The stock initially rose modestly during the day before plummeting over 33% by market close as investors digested the revenue miss and dilutive financing. The timing of the offering alongside disappointing near-term performance created a negative narrative that overshadowed longer-term AI opportunities.

AEON

AEON Biopharma, Inc.Healthcare

$0.50−$0.20

-28.2%

AMEX · Mkt cap $9.9 M

AEON Biopharma fell 28.24% with no news reported in the last 48 hours, making the specific catalyst unclear; the drop likely reflects either a delayed market reaction to an earlier announcement, technical selling, or negative developments not yet captured in news feeds.

No headlines were found in the last 48 hours to explain AEON's sharp 28% decline. For a small-cap biotech stock trading at $0.50, typical catalysts include clinical trial results, regulatory decisions, financing announcements, or management changes. Given the stock's position as the fourth-biggest loser of the day, the move appears material and not random noise. The absence of any news coverage suggests either that the catalyst predates the 48-hour window, that a negative development occurred but hasn't yet been widely reported, or that heavy technical selling or short covering drove the decline. Without access to earlier news archives or real-time market commentary, the precise cause remains uncertain.

ABVC

ABVC BioPharma, Inc.Healthcare

$1.45−$0.57

-28.2%

NASDAQ · Mkt cap $24 M

No news headlines were available in the last 48 hours to explain the 28.22% drop in ABVC, making the specific catalyst unclear, though biotech microcaps are sensitive to clinical data, financing announcements, or broader sector weakness.

The absence of any recent news in the provided headlines makes it impossible to identify a specific announced catalyst for ABVC's sharp decline. Biotech companies, particularly smaller ones trading near $1.45, typically experience large single-day moves in response to several event categories: clinical trial results (positive or negative), financing announcements (dilutive offerings), FDA decisions on pipeline candidates, partnership developments, or sector-wide selloffs affecting small-cap biotechs. It is also possible the move reflects delayed market reaction to news released outside the 48-hour window captured here, or an intraday rumor that has not yet appeared in formal headlines. Without concrete information, we cannot distinguish between these possibilities.

TVRD

Tvardi Therapeutics, Inc.Healthcare

$3.80−$1.20

-24.0%

NASDAQ · Mkt cap $25 M

TVRD dropped 24% today despite positive phase I data and a Raymond James upgrade announced in the last 48 hours, suggesting profit-taking after a 149% weekly rally or a delayed negative catalyst not yet reflected in the provided headlines.

The recent news headlines are uniformly positive: phase I data for TTI-109 showed improved tolerability and target engagement, Raymond James upgraded TVRD to outperform on July 8, and the stock had rallied 149% earlier in the week. However, the stock is now the sixth biggest loser of the day, down 24%. This disconnect suggests either a sharp reversal in sentiment driven by information not captured in the provided headlines, profit-taking after an extreme rally, or a technical correction. Biotech stocks are volatile and can reverse sharply on perceived risk regarding trial outcomes, manufacturing, financing, or competitive dynamics. The timing of the drop the same day as the positive headline suggests either that headline oversimplified a more complex earnings call or clinical data presentation, or that a separate negative announcement or market-wide biotech selloff occurred after the headlines were published.

IONS

Ionis Pharmaceuticals, Inc.Healthcare

$64.27−$20.19

-23.9%

NASDAQ · Mkt cap $9.7 B

Ionis stock crashed 23.9% after its Wainua heart drug failed to meet the primary endpoint in the Phase 3 CARDIO-TTRansform trial with partner AstraZeneca, eliminating multibillion-dollar commercial expectations for this gene-silencing therapy.

The headlines establish a clear and material catalyst: AstraZeneca and Ionis announced on July 9 that Wainua (eplontersen) failed to reduce heart events in its late-stage trial, missing the main goal. This is a Phase 3 failure for a rare heart disease treatment that had been positioned as a significant commercial opportunity. AstraZeneca itself fell as much as 9.9 percent, losing over £20 billion in market value, though it recovered somewhat. Ionis's steeper decline relative to AstraZeneca reflects that this candidate represented a larger percentage of Ionis's pipeline value and partnership revenue potential. The failure eliminates near-term regulatory and revenue catalysts and raises questions about the entire asset's viability. One peer, BBIO, surged 16 percent, likely reflecting competitive relief.

GLOO

Gloo Holdings, Inc.Technology

$3.04−$0.94

-23.6%

NASDAQ · Mkt cap $292 M

Gloo announced pricing of a public stock offering on July 9, which typically causes immediate shareholder dilution and selling pressure, explaining the 23.62% single-day decline.

The headline confirms Gloo priced a public offering of Class A Common Stock on the morning of July 9, 2026. Public offerings create immediate dilution to existing shareholders because new shares are issued and sold into the market, reducing ownership percentage and earnings per share. The timing of the announcement coinciding precisely with the largest single-day drop suggests market participants sold on the news or were forced to rebalance. The headline is truncated and does not disclose offer size, pricing details, or use of proceeds, but the dilution mechanism is well-established and explains sharp declines in the hours following such announcements. No competing news (earnings, guidance, M&A, regulatory action) is provided to suggest an alternative cause.

CYAB

Cyabra, Inc. Common StockTechnology

$0.34−$0.09

-21.6%

NASDAQ · Mkt cap $5.2 M

Cyabra announced a $6 million private placement at a premium to market price coupled with mandatory preferred-to-common conversion, which typically dilutes existing shareholders and signals potential distress, likely driving the 21.57% single-day sell-off.

The headline reveals two equity dilution mechanisms occurring simultaneously. First, the company is raising $6 million via private placement priced above the current market price, which is ostensibly positive but in context suggests capital needs. Second, and more significantly, all outstanding preferred shares will convert to common stock or equivalents subject to stockholder approval. Preferred conversions often indicate the preferred holders are exiting or restructuring their positions, and forced conversion into common dilutes the ownership base. The phrase "existing shareholder, as well as" suggests insider participation, which may signal confidence but also can raise concerns about terms. For a micro-cap trading at $0.34, any dilution event combined with capital raise signals financial stress or restructuring, triggering broad sell pressure. The magnitude of the decline aligns with classic dilution-driven equity reactions in illiquid small-cap stocks.

YMAT

J-Star Holding Co., Ltd. Ordinary SharesBasic Materials

$0.38−$0.10

-20.9%

NASDAQ · Mkt cap $7.3 M

J-Star announced a 1-for-5 share consolidation on July 8, which typically triggers a mechanical price adjustment and may signal underlying business concerns, explaining the 20.93% single-day drop.

The headline confirms J-Star announced a 1-for-5 share consolidation effective July 8, 2026. Share consolidations are mechanical events: every five old shares become one new share, so the quoted price should theoretically rise fivefold to maintain equal market capitalization. However, the stock fell sharply instead. This discrepancy suggests two overlapping drivers. First, the market may be interpreting the consolidation as a negative signal—consolidations are often used by troubled companies to maintain minimum listing standards or improve optics before raising capital or restructuring. Second, there may be temporary confusion or forced selling around the ex-date adjustment. Without additional context on J-Star's financial health or the stated purpose of the consolidation, the most likely explanation is negative market sentiment toward the consolidation itself as a proxy for company distress rather than a pure technical repricing.

CCHH

CCH Holdings Ltd Ordinary SharesConsumer Cyclical

$0.21−$0.05

-20.2%

NASDAQ · Mkt cap $4.3 M

CCH Holdings announced a 1-for-10 share consolidation on July 9, which mechanically reduces share count and resets the nominal price; the 20% drop likely reflects market disappointment that consolidation alone does not address underlying business fundamentals, despite CEO's confidence signals fro…

On July 8, the CEO announced plans to repurchase $10 million to $30 million of shares at not less than $1.00 per share, signaling management confidence. However, the next day CCH announced a 1-for-10 share consolidation, a corporate action that combines 10 existing shares into 1 new share and proportionally increases the nominal share price. The stock closed at $0.21, down 20.24%, which is consistent with pre-consolidation shares trading below the $1.00 buyback floor the CEO had just announced. The market's sharp negative reaction suggests investors view the consolidation as a defensive maneuver—an attempt to engineer compliance with minimum bid price requirements or to improve optics—rather than evidence of genuine operational improvement. The consolidation itself creates no new value; it merely resets the share structure. Combined with the stock's position as the 11th biggest loser, this indicates broad skepticism about whether either the buyback or consolidation addresses the underlying challenges facing the Malaysia-based restaurant chain.

ZCMD

Zhongchao Inc.Healthcare

$2.02−$0.48

-19.2%

NASDAQ · Mkt cap $6.2 M

No news headlines were found in the last 48 hours, so the 19.20% drop cannot be attributed to a specific announced event. The decline likely stems from technical selling, broader market weakness, or undisclosed company developments.

The absence of recent news headlines makes it impossible to point to a concrete catalyst for ZCMD's steep 19.20% decline on July 9, 2026. For a micro-cap or small-cap stock like this, price moves of this magnitude without identifiable news can reflect several common drivers: technical selling triggered by a break of support levels, broad market downturns affecting smaller equities disproportionately, short covering or forced liquidations, or delayed disclosure of negative developments that market participants may have learned of through channels other than official news. Without additional context on the company's fundamentals, recent earnings, short interest, or trading patterns, we cannot distinguish among these possibilities. The rank as the 12th biggest loser suggests sector-wide or market-wide stress rather than company-specific isolation, but that too remains inference.

VTAK

Catheter Precision, Inc.Healthcare

$1.14−$0.23

-16.8%

AMEX · Mkt cap $770 K

No news directly tied to VTAK appeared in the provided headlines. The 16.79% drop on July 9 likely reflects sector weakness, technical selling, or an unannounced catalyst not captured in the Yahoo Finance RSS feed.

The only headline provided concerns Flyte and LifeVac partnering on aircraft safety equipment, which has no apparent connection to Catheter Precision (VTAK), a medical device company focused on catheter systems. The absence of company-specific news makes it difficult to pinpoint the cause of the sharp decline. Micro-cap stocks like VTAK trading on AMEX are often sensitive to liquidity events, insider selling, failed clinical or commercial milestones, cash runway concerns, or broader biotech sector selloffs. Without access to intraday trading data, SEC filings, or company announcements released on July 8–9, the actual trigger remains unclear. The ranking as the 13th biggest loser suggests this was a significant move, potentially driven by material news that simply did not appear in the RSS feed checked.

KIDZ

KIDZ AI Inc.Consumer Defensive

$0.70−$0.13

-16.2%

DXF

Eason Technology LimitedFinancial Services

$0.58−$0.11

-16.0%

AMEX · Mkt cap $1.6 M

DXF fell 16% on 2026-07-09 with no news reported in the last 48 hours, so the immediate catalyst is unknown; the drop may reflect technical selling, delayed reaction to unreported events, or sector headwinds.

No headlines were found in the last 48 hours covering DXF or Eason Technology Limited, making it impossible to identify a specific news-driven catalyst for the 15.99% decline. This is a micro-cap stock trading at $0.58, which typically exhibits higher volatility and thinner liquidity than larger-cap securities. Stocks at this price point often move on retail sentiment, technical breakdowns through support levels, sector rotation, or undisclosed news that has not yet been picked up by major financial newswires. Without access to insider trading reports, short-seller activity, regulatory filings, or specialized industry news, the most likely explanations are technical selling, accumulated selling pressure from prior days now realized, or a negative announcement that simply has not yet appeared in the RSS feeds checked.

TCRX

TScan Therapeutics, Inc.Healthcare

$1.06−$0.20

-15.9%

NASDAQ · Mkt cap $49 M

No news headlines were found in the last 48 hours, so the 15.87% drop cannot be attributed to a specific disclosed event. Biotech micro-caps like TCRX often experience sharp moves on clinical data, financing developments, or market sentiment shifts.

TCRX dropped sharply with no corresponding news in the prior 48 hours according to available RSS feeds. This is not uncommon for small-cap biotech stocks, which can be sensitive to clinical trial outcomes, regulatory decisions, capital raises, or shifts in sector sentiment that may not immediately appear in major news aggregators. The stock trades at $1.06, suggesting it has faced prior pressure. Possible catalysts include delayed disclosure of clinical results, an untracked financing announcement, insider selling, short covering reversals, or broad biotech sector weakness. Without confirmed headlines, any specific cause remains speculation. Investors should check SEC filings, the company website, and press releases directly for the actual trigger.

APACR

StoneBridge Acquisition II Corporation

$0.13−$0.02

-15.5%

AMPGZ

Amplitech Group, Inc. Series B Right

$1.13−$0.20

-15.0%

NASDAQ

A positive product demonstration announcement from yesterday did not prevent a 15% drop in AMPGZ today, suggesting the decline is driven by factors unrelated to the favorable news about the 64T64R Massive MIMO radio.

The only recent news is a July 8 press release announcing that AmpliTech's 64T64R Massive MIMO radio was featured in live demonstrations at an industry-first AI-RAN Alliance test facility, framed as a notable achievement. This is positive news, yet the stock fell 15% the following day. This disconnect indicates the decline is not caused by the headline provided. AMPGZ is a Series B Right unit, a derivative security with its own mechanics around exercise price, expiration, and implied volatility. The drop could reflect broader weakness in Amplitech Group equity, a decline in the value of the underlying common shares, or changes in implied volatility of the parent stock. Without additional market data or news from today, the specific catalyst remains unclear.

FMACR

Future Money Acquisition Corporation Rights

$0.17−$0.03

-15.0%

NASDAQ

No news headlines were found in the last 48 hours to explain the 14.95% drop in FMACR. The decline likely reflects typical volatility in blank-check company rights or a delayed reaction to prior developments.

The absence of recent news headlines makes it difficult to pinpoint a specific catalyst for today's decline. FMACR is a rights offering from a Special Purpose Acquisition Company (SPAC), a security class known for elevated volatility and sensitivity to shifts in deal sentiment, redemption announcements, or changes in the underlying company's prospects. Rights offerings typically trade thinly and can move sharply on limited volume or sentiment shifts tied to the parent SPAC's performance or merger timeline. Without identified news, the drop could reflect general profit-taking, deterioration in investor appetite for blank-check deals, or a prior announcement from one or two days ago that has not yet surfaced in the RSS feed provided. Technical selling or redemption-related pressure are also plausible drivers for this asset class.

LMFA

LM Funding America, Inc.Financial Services

$0.13−$0.02

-14.6%

NASDAQ · Mkt cap $1.5 M

LMFA dropped 14.65% despite a headline announcing strategic expansion into AI and high-performance computing on the same day, suggesting market skepticism about the pivot or unrelated selling pressure.

The headline from July 9 announces LMFA's expansion into high-performance computing and AI, framed positively as part of a list of best crypto penny stocks. However, the stock fell sharply the same day, which typically indicates the market either lacks confidence in the strategic pivot, questions execution capability, or is responding to a separate negative catalyst not captured in the headline snippet. The headline text is incomplete, cutting off mid-sentence, so key details about funding, timeline, or technical viability may be missing. For a micro-cap penny stock trading at $0.13, expansion announcements often trigger selling if they appear dilutive, lack financial backing, or signal desperation rather than genuine strategic progress. Alternatively, the decline could reflect broader market conditions, sector rotation out of crypto-adjacent stocks, or concentrated holders liquidating positions unrelated to the announcement itself.

ENRD

Einride ABTechnology

$6.97−$1.18

-14.5%

NASDAQ · Mkt cap $863 M

No news headlines were found in the last 48 hours to explain Einride's 14.48% drop, so the cause remains unclear from publicly available information.

Einride is an autonomous electric vehicle technology company, and a single-day 14% decline without accompanying headlines in the news feed is difficult to attribute to a specific catalyst. The absence of reported news does not rule out a private company announcement, earnings release, analyst downgrade, or sector-wide selloff in EV or transportation stocks that may not yet be widely indexed. It could also reflect technical selling, options expiration pressure, or a delayed market reaction to news from an earlier period. Without access to the full news universe or intraday market context, attributing the move to a particular cause would be speculative. EV and cleantech stocks are sensitive to macro sentiment, regulatory developments, and competitive positioning, but none of those categories can be confirmed from the available evidence.

ONFO

Onfolio Holdings, Inc.Communication Services

$0.24−$0.04

-14.5%

NASDAQ · Mkt cap $334 K

Onfolio announced a transformational deal to access a $3 billion helium resource via Paramount Helium, yet the stock fell 14.47%, suggesting investor skepticism about deal execution, dilution from the combination, or valuation concerns despite the strategic upside.

Onfolio released two headlines on July 8-9 announcing a letter of intent to combine with Paramount Helium, positioning the company to access substantial US-based helium assets targeting semiconductor, space, and aerospace markets. Ordinarily, a transformational strategic transaction would be met with optimism, but the sharp 14.47% decline indicates the market is discounting the announcement. Possible explanations include concern about deal structure and shareholder dilution, uncertainty around the $3 billion resource valuation or its development timeline, questions about Onfolio's ability to execute, or a lack of confidence that helium market demand justifies the combination at current valuations. The stock is already trading at $0.24, suggesting it is either a penny stock with structural challenges or a distressed name, which could amplify negative sentiment around execution risk in M&A.

AIIO

Robo.ai Inc.Consumer Cyclical

$3.40−$0.56

-14.1%

NASDAQ · Mkt cap $487 M

No news headlines were available in the last 48 hours to explain AIIO's 14.14% single-day drop, so the catalyst remains unclear without additional context or market data.

The absence of any recent news headlines makes it impossible to identify a specific fundamental trigger for today's decline. AIIO is a robotics and AI-focused company, and stocks in this sector can be sensitive to several categories of catalysts: broad tech sector selloffs, changes in AI sentiment or valuation multiples, disappointing updates on product launches or partnerships, analyst downgrades or coverage changes, insider selling or dilution announcements, or macroeconomic shifts affecting growth-stage companies. A 14% single-day move in a lower-cap NASDAQ name is material enough to suggest either a concrete event (missed guidance, executive departure, financing announcement) or a sharp shift in market sentiment. Without access to after-hours disclosures, analyst notes, or real-time market commentary, the specific driver cannot be determined from the information provided.

BUUU

BUUU Group LtdIndustrials

$18.28−$3.00

-14.1%

NASDAQ · Mkt cap $474 M

No news headlines were found in the last 48 hours to explain BUUU's 14.1% decline, so the catalyst remains unclear from publicly reported sources.

BUUU Group Ltd dropped 14.1% to $18.28 with no identifiable news catalyst in the recent news feed. Without headlines, we cannot point to a specific earnings miss, guidance cut, regulatory action, or business development. The decline could stem from several categories: a delayed market reaction to older news not captured in this snapshot, broad sector weakness, technical selling pressure, an unannounced insider development, or market sentiment shift toward the company's business model. Without access to real-time trading data, social media discussions, or company press releases outside the Yahoo Finance RSS feed, the precise trigger is unknown. Investors seeking clarity would need to check the company's investor relations page, recent SEC filings, or trading halt announcements.

PLBL

Polibeli Group LtdConsumer Cyclical

$6.42−$1.05

-14.1%

NASDAQ · Mkt cap $2.2 B

Polibeli announced a non-binding MOU to explore an AI computing center in Thailand, but the stock fell 14% despite the news being released the same day, suggesting market skepticism about execution risk or a lack of material substance in the early-stage agreement.

The headline reveals that Polibeli signed a non-binding memorandum of understanding with a Thailand-based partner to explore a large-scale AI computing center project. The news was released on 2026-07-09, the same day as the sharp decline. While AI projects can attract investor interest, a non-binding MOU is explicitly preliminary and carries no contractual obligation or guaranteed economics. The 14% drop despite the news suggests either the market viewed the announcement as insufficient in substance (lacking specifics on funding, timeline, or partner identity), or investors may have expected more concrete terms. Alternatively, the decline could reflect profit-taking after recent gains or broader sector weakness unrelated to this specific announcement. The term "explores" further signals uncertainty about project viability.

TRNR

Interactive Strength Inc.Consumer Cyclical

$2.58−$0.42

-14.0%

NASDAQ · Mkt cap $4.2 M

Interactive Strength published an upbeat investor deck with 67% revenue guidance hike to $50M+, yet the stock fell 14%, suggesting the market either doubts execution, views the revised guidance as insufficient, or reacted to dilution concerns tied to the acquisition strategy mentioned.

The headline reports genuinely positive news: a substantial increase in 2026 pro forma revenue guidance to over $50 million and a path to Adjusted EBITDA profitability by Q4 2026. Ordinarily such an announcement would support the stock price. The 14% decline therefore indicates investor skepticism about credibility, execution risk on the stated acquisition strategy, or concern that the company may need to raise capital or dilute shareholders to fund those acquisitions. Another possibility is that the guidance, while raised, still fell short of market expectations or analyst estimates. Without access to pre-announcement consensus estimates or details on dilution, the most probable inference is that the market is discounting the optimistic pro forma numbers as unachievable or pricing in shareholder dilution costs that outweigh the revenue upside.

CABO

Cable One, Inc.Communication Services

$35.27−$5.60

-13.7%

NYSE · Mkt cap $147 M

Cable One shares fell 13.70% on July 9, 2026, with no news headlines in the last 48 hours to explain the move. The decline likely stems from broad market weakness, sector-specific pressure in cable/broadband, or a delayed corporate announcement not yet reflected in public news feeds.

No news headlines were found in the 48 hours preceding this significant 13.70 drop, which limits our ability to identify a specific catalyst. Cable One is a cable and broadband provider, a sector sensitive to earnings misses, subscriber loss, competitive pressure, and changes in broadband pricing or regulation. A move of this magnitude typically reflects either a material corporate event (earnings report, guidance cut, activist involvement, or large insider selling) or exogenous market stress. It is also possible that a news release was issued but has not yet propagated to the RSS feed, or that the decline is a delayed market reaction to information released prior to the 48-hour window. Without direct evidence, we cannot determine whether this is idiosyncratic to CABO or symptomatic of broader telecom weakness.

FBYD

Falcon's Beyond Global, Inc. Class A Common StockIndustrials

$15.34−$2.37

-13.4%

NASDAQ · Mkt cap $387 M

FBYD dropped 13.38% with no news reported in the last 48 hours, suggesting the move was driven by technical selling, market-wide pressure, or an unannounced corporate event.

No headlines were available in the last 48 hours to explain the 13.38% single-day decline. For a company like Falcon's Beyond Global, which operates in the experiential entertainment and theme park space, typical catalysts for sharp intraday losses include earnings misses or guidance reductions, changes in capital structure or dilution announcements, broader sector weakness, or unexpected operational challenges. Without news coverage, the move cannot be attributed to any identifiable corporate action or market event captured in the available data. The absence of commentary itself is noteworthy and suggests either a very recent announcement that has not yet been picked up by mainstream financial media, or a purely technical or sentiment-driven selloff.

NOAH

Noah Holdings LimitedFinancial Services

$8.90−$1.35

-13.2%

NYSE · Mkt cap $607 M

No news headlines were found in the last 48 hours to explain Noah Holdings' 13.17% decline, so the cause remains unclear without additional market context or internal company developments.

Noah Holdings, a Chinese wealth management and asset management firm, experienced a significant single-day drop of over 13 percent on July 9, 2026, yet no news headlines from the prior 48 hours are available to directly explain the move. The stock operates in a sector sensitive to regulatory changes in China, shifts in asset management fee structures, client redemptions, and macroeconomic conditions affecting high-net-worth individuals in Asia. Without specific news, the decline could reflect delayed reactions to earlier announcements, intraday market momentum, broader emerging-market weakness, Chinese regulatory headwinds, or client-specific capital flows. Wealth management firms are particularly vulnerable to sentiment shifts around policy uncertainty or economic data that might affect investor risk appetite.

SKYQ

Sky Quarry Inc.Energy

$3.32−$0.50

-13.1%

NASDAQ · Mkt cap $12 M

Sky Quarry appointed a refining industry veteran as president of its subsidiary on the same day the stock dropped 13%, but the appointment itself is a positive personnel move; the decline likely reflects broader market sentiment, profit-taking, or undisclosed negative catalysts unrelated to this …

The only headline provided is a personnel announcement: Ray Hansen, a former HF Sinclair executive with 35+ years of experience, was appointed President of Foreland Refining Corporation. This is typically framed as a positive development signaling operational strengthening and growth confidence. The timing of the announcement (9:00 AM UTC on July 9) preceded a 13% intraday decline, but the announcement itself contains no negative information—no earnings miss, no guidance cut, no operational failure, no contract loss. The disconnect suggests either that (a) market participants viewed the move as insufficient to address underlying concerns, (b) the stock faced selling pressure from unrelated technical, sector-wide, or company-specific factors not captured in these headlines, or (c) there was a separate negative catalyst announced or rumored that the RSS feed did not capture.

ZSTK

Flora Growth Corp.Financial Services

$2.49−$0.37

-12.9%

NASDAQ · Mkt cap $32 M

ZeroStack Corp. announced a $14.7 million pharmaceutical inventory purchase order deal on July 9, yet the stock fell 12.88%, suggesting the market viewed the news as insufficient or disappointing relative to expectations or valuation.

The company released a genuine business development announcement—securing purchase orders worth up to $14.7 million from two pharmaceutical companies—which would normally be considered positive news for a smaller-cap AI and asset management firm. However, the stock declined sharply on the same day the news was published, indicating the market's reaction was negative or indifferent. This disconnect suggests several possibilities: the deal size may have underwhelmed relative to prior guidance or analyst expectations, investor sentiment toward the stock or sector may have shifted, or the announcement may have been perceived as weaker than the market required to justify current valuation. Without prior analyst consensus or company guidance figures, we cannot definitively determine whether the news itself was disappointing in substance or whether external factors (sector rotation, broader market weakness, or other concurrent news) drove the decline. The fact that the stock ranks as the 31st biggest loser suggests a material negative catalyst, but the provided headline alone does not fully explain the magnitude of the move.

NKTX

Nkarta, Inc.Healthcare

$3.21−$0.46

-12.5%

NASDAQ · Mkt cap $182 M

No news headlines are available in the last 48 hours to explain the 12.53% drop, so the cause remains unclear without additional context on company-specific events, sector moves, or market conditions on July 9, 2026.

Nkarta is a clinical-stage cell therapy company, and biotech stocks are typically sensitive to clinical trial data, regulatory decisions, financing announcements, and broader sector sentiment. The absence of news in the RSS feed over the last 48 hours does not rule out earlier developments that may have circulated through other channels, investor calls, or SEC filings that took time to reflect in equity pricing. Alternatively, the move could stem from sector-wide weakness in cell therapy or immunotherapy stocks, a broader market decline on July 9, or technical selling around a key support level. Without headlines, it is difficult to distinguish between company-specific bad news and macro or sector headwinds. A same-day earnings miss, trial stoppage, or financing dilution would be typical catalysts for a biotech decline of this magnitude, but the evidence does not confirm any of these.

GVA

Granite Construction IncorporatedIndustrials

$125.58−$17.94

-12.5%

NYSE · Mkt cap $5.3 B

GVA fell 12.5% on July 9, but the provided headline from July 8 discusses a road-paving company stuck in a perception gap despite strong performance—likely referring to a peer or the broader sector rather than establishing a specific catalyst for today's drop.

The single headline provided discusses a road-paving company with explosive growth but stagnant stock price, describing a "quiet standoff between performance and perception." This appears to be sector commentary rather than company-specific news about GVA itself. The headline does not identify any earnings miss, contract loss, guidance cut, accident, regulatory action, or other concrete event tied to GVA. A 12.5% single-day drop in a construction stock typically reflects either a major operational announcement (project loss, cost overrun, accident), financial guidance revision, earnings disappointment, or broader market rotation out of cyclicals or construction equities. Without explicit confirmation in the headlines, the cause remains unclear. The reference to perception lagging performance suggests possible valuation repricing or sector rotation, but this is inference rather than fact.

APVO

Aptevo Therapeutics Inc.Healthcare

$3.94−$0.56

-12.4%

NASDAQ · Mkt cap $4.1 M

No news headlines were found in the last 48 hours, so the 12.44% drop cannot be attributed to a specific announced catalyst; the decline likely reflects either market-wide pressure, technical selling, or an undisclosed development in this small-cap biotech company.

Aptevo Therapeutics is a clinical-stage biopharmaceutical company with a market cap typically under $50 million, making it highly sensitive to sentiment shifts and technical moves even without major news events. The absence of any headlines in the last 48 hours suggests the decline was not driven by an earnings miss, regulatory action, or strategic announcement that Yahoo Finance captured. For a micro-cap biotech, common catalysts for sharp one-day drops include dilutive financing announcements, clinical trial setbacks, key personnel changes, or shifts in sector momentum that may not immediately surface in aggregated news feeds. The rank as the 34th biggest loser suggests it underperformed the market significantly today, which in a small-cap context can reflect either sector-wide biotech weakness or company-specific pressure that precedes formal disclosure.

CPOP

Pop Culture Group Co., LtdCommunication Services

$0.06−$0.01

-12.4%

NASDAQ · Mkt cap $4.8 M

Pop Culture Group announced a 10-for-1 share consolidation on July 8, which likely triggered the 12.43% single-day drop as investors reacted to the dilutive capital restructuring and associated uncertainty.

The company announced a share consolidation (reverse split at 10:1 ratio) on July 8, 2026. While reverse splits are technically non-dilutive in per-share terms, they are often perceived negatively by markets because they signal financial distress, low stock price, or a desperate attempt to regain exchange compliance. The timing of the announcement with the same-day drop suggests immediate market reaction. Investors may have interpreted the consolidation as a precursor to additional capital raises, dilutive equity offerings, or acknowledgment of fundamental business challenges. The stock's status as the 35th biggest loser suggests broader selling pressure consistent with a significant corporate action announcement rather than isolated sector weakness.

HCICR

Hennessy Capital Investment Corp. VIII Share Rights

$0.17−$0.02

-12.4%

NASDAQ

No news headlines were found in the last 48 hours to explain the 12.37% decline in HCICR, making the specific catalyst unclear without additional market data or internal developments.

HCICR is a share rights offering associated with Hennessy Capital Investment Corp. VIII, a blank-check acquisition vehicle. The absence of any recent news headlines makes it difficult to pinpoint the exact cause of today's decline. However, SPAC-related securities are sensitive to several recurring factors: shifts in redemption expectations, deterioration in confidence regarding the sponsor's deal sourcing, changes in interest rates affecting blank-check economics, or broad sector rotation out of speculative equity structures. Additionally, rights offerings can experience erosion if the underlying SPAC stock weakens or if market participants believe the strike price or terms have become less attractive. Without contemporaneous reporting or earnings data, the decline could reflect routine illiquidity, algorithmic selling, or a delayed market reaction to news published outside the 48-hour window.

VACH

Voyager Acquisition Corp.Financial Services

$2.42−$0.34

-12.3%

AVXX

Defiance Daily Target 2X Long AVAV ETF

$5.33−$0.74

-12.2%

NASDAQ

No news headlines were available in the last 48 hours. AVXX is a 2X leveraged ETF tracking AVAV (AeroVironment), so the -12.19% drop likely reflects a roughly -6% decline in the underlying stock amplified by leverage, though broader market weakness or sector rotation cannot be ruled out without i…

Yahoo Finance returned no news items for AVXX in the last 48 hours, making direct attribution impossible. However, AVXX is a daily reset leveraged long ETF, meaning it is designed to deliver twice the daily performance of its underlying index or security. A -12.19% move in the ETF is consistent with approximately a -6% move in the underlying AVAV stock, factoring in the 2X leverage multiplier. The absence of named headlines does not prove absence of a catalyst; the move could reflect earnings results, guidance revision, contract loss, analyst downgrade, or sector-wide weakness in defense aerospace that simply has not yet been picked up by the Yahoo Finance RSS feed as of the snapshot date. Without access to AVAV's own price action or intraday news, the true driver remains unknown.

ALXO

ALX Oncology Holdings Inc.Healthcare

$2.06−$0.27

-11.6%

NASDAQ · Mkt cap $285 M

ALXO fell 11.59% on July 9, 2026, but the single news headline provided is about BIAF (bioAffinity), not ALXO directly, making the specific cause of this drop unclear from available evidence.

The headline discussing BIAF's CyPath Lung sales and regulatory/funding pressures is unrelated to ALXO specifically and does not explain ALXO's decline. However, both are oncology-focused biotechnology stocks operating in competitive spaces with similar risk profiles—regulatory uncertainty, cash burn, and clinical/commercial execution risk. ALXO's 11.59% single-day drop is material but not unusual for small-cap biotech stocks, which are sensitive to clinical data releases, regulatory decisions, financing announcements, competitive developments, or broad sector sentiment shifts. Without headlines directly tied to ALXO, the catalyst remains unidentified. Possibilities include adverse trial data, a secondary offering, competitive news, or broader biotech sector weakness, but these are inferences rather than confirmed facts.

LVWR

LiveWire Group, Inc.Consumer Cyclical

$0.71−$0.09

-11.5%

NYSE · Mkt cap $254 M

No news headlines were found in the last 48 hours explaining the 11.55% decline in LiveWire Group stock, making the cause unclear without additional information.

LiveWire Group is an electric motorcycle manufacturer spun out from Harley-Davidson, operating in a capital-intensive, cyclical sector with limited mainstream adoption. The absence of any news in the last 48 hours does not rule out a catalyst—the market may be reacting to a delayed disclosure, analyst downgrade, or broader sector weakness in EV/motorcycle stocks that lacks a specific headline. Alternatively, the decline could reflect technical selling, short covering reversal, or accumulation of negative sentiment from an earlier period. Without access to the specific news feed timing or any company filings, options like earnings results from other motorcycle makers, quarterly guidance adjustments, or changes in EV subsidies are plausible but unconfirmed categories of cause rather than established fact.

BOIL

ProShares Ultra Bloomberg Natural Gas

$23.68−$3.09

-11.5%

ICG

Intchains Group LimitedTechnology

$0.80−$0.10

-11.4%

NASDAQ · Mkt cap $53 M

No news headlines were found in the last 48 hours to explain ICG's 11.44% drop, so the decline likely stems from technical selling, a delayed announcement, or broader market conditions not captured in available headlines.

The absence of any news in the last 48 hours makes it impossible to attribute ICG's significant single-day loss to a specific corporate event. For a micro-cap stock trading at $0.80, common catalysts that do not always generate immediate press coverage include executive departures, regulatory filings, insider selling activity, margin calls affecting major holders, or negative broker research reports that circulate before formal publication. Alternatively, the decline could reflect technical selling pressure if the stock had run up recently, a delay in expected earnings or guidance, or contagion from sector weakness that may not have triggered individual stock headlines. Without verifiable news, any explanation remains speculative.

HODO

Brag House Holdings, Inc.Technology

$1.39−$0.18

-11.2%

NASDAQ · Mkt cap $33 M

No news headlines were found in the last 48 hours for HODO, so the 11.22% drop cannot be directly attributed to a reported company-specific event. The decline may reflect technical selling, sector rotation, or unannounced developments not yet captured in major news feeds.

The absence of any news in the last 48 hours makes it impossible to link the sharp 11.22% decline to a specific catalyst. For a micro-cap stock like Brag House Holdings trading at $1.39, typical causes of large single-day drops without concurrent headlines include profit-taking from prior momentum, technical support breaking down, broad market weakness affecting small caps disproportionately, or rumors circulating on social media and message boards that have not yet reached mainstream financial news. Without access to short interest data, insider trading activity, or real-time social sentiment, we cannot determine which of these factors drove the move. The stock's low price point and NASDAQ listing suggest it may be subject to higher volatility and retail trading dynamics.

Lands' End, Inc.Consumer Cyclical

$10.71−$1.35

-11.2%

NASDAQ · Mkt cap $381 M

No news headlines were available in the last 48 hours to explain Lands' End's 11.19% drop, so the catalyst remains unclear from public announcements alone.

The absence of recent news makes it difficult to pinpoint a specific catalyst for this substantial single-day decline. Lands' End is a mature retail apparel company, and moves of this magnitude typically stem from earnings misses or warnings, comparable store sales disappointments, margin compression signals, or negative comparable company developments. Without headline evidence, the drop could reflect delayed market reaction to prior news, a sector-wide retail headwind, technical selling pressure, or an unannounced development that has not yet appeared in the news feed. Retail stocks have been volatile in 2026, and apparel retail in particular faces structural headwinds from e-commerce competition and consumer discretionary spending shifts. The lack of confirming headlines suggests either the news has not yet been publicly released or the move is driven by non-news factors such as technical levels, short covering, or algorithmic trading.

AIAI

AIAI Holdings Corporation Class A Common StockIndustrials

$11.28−$1.42

-11.2%

NASDAQ · Mkt cap $367 M

AIAI Holdings fell 11.18% despite launching Gate AI, a new security product for AI applications, announced on July 8th. The disconnect between positive product news and sharp selling suggests the market either viewed the announcement as insufficient to justify valuation or reacted to separate neg…

The company announced Gate AI, a security gateway product offering prompt injection protection and cost reduction features, on July 8th at 12:30 UTC. This is ostensibly positive news for a company in the AI space. However, the stock dropped sharply the following day, ranking 45th among NASDAQ losers. The disconnect warrants careful interpretation. The product launch itself appears genuine and substantive, but the market may have discounted it for several reasons: investor skepticism about near-term revenue impact, concerns about competitive differentiation in the crowded AI security market, or a broader market pullback in AI-related equities that day. Alternatively, the sell-off may be entirely unrelated to the announcement and driven by separate factors such as insider selling, technical breakdown, or broader sector rotation away from smaller-cap AI plays.

VATE

INNOVATE Corp.Industrials

$10.16−$1.27

-11.1%

NYSE · Mkt cap $107 M

VATE dropped 11% likely due to market disappointment over DBM Global's cash dividend announcement, which signals capital return instead of reinvestment for growth, or negative sentiment toward the parent company itself unrelated to the dividend news.

The only news in the past 48 hours is that INNOVATE Corp.'s subsidiary DBM Global announced a cash dividend. On its surface, a dividend announcement is typically neutral to slightly positive for investors, as it demonstrates cash generation and shareholder-friendly capital allocation. However, a sharp 11% single-day drop suggests the market may have interpreted the dividend negatively—either viewing it as a sign of limited growth opportunities at DBM Global, concern about INNOVATE's ability to deploy capital productively, or possibly disappointment with dividend size or payout terms relative to expectations. Alternatively, the drop may reflect broader negative sentiment toward INNOVATE itself that the dividend announcement merely coincided with rather than caused. Without additional context on dividend yield, payout ratio, or concurrent guidance changes, the exact mechanism remains unclear.

FTRK

Fast Track GroupCommunication Services

$0.37−$0.05

-10.9%

NASDAQ · Mkt cap $3.0 M

No news headlines were available in the last 48 hours to explain Fast Track Group's 10.93% decline on July 9, 2026. The drop likely stems from technical selling, general market weakness, or undisclosed company developments not yet picked up by major news feeds.

The absence of recent headlines in the provided data means there is no direct news catalyst to point to for today's 10.93% drop in FTRK stock. At this price level ($0.37), this is a micro-cap or penny stock, which typically exhibits higher volatility and can move sharply on relatively low volume without coordinated news coverage. Possible explanations include routine technical selling following prior gains, a broader sector or market downturn not visible in this snapshot, undisclosed insider transactions, or delayed reporting of company announcements that have not yet reached major financial news feeds. Without additional context on the company's business, recent earnings, or any regulatory filings, attributing this move to a specific catalyst would be speculative.

CABR

Caring Brands, Inc.Healthcare

$1.32−$0.16

-10.8%

NASDAQ · Mkt cap $12 M

No news headlines were found in the last 48 hours for CABR, so the 10.81% drop cannot be directly attributed to a specific company announcement or event reported by major financial outlets.

The absence of recent news makes it impossible to identify a concrete catalyst for today's decline. CABR is a small-cap stock trading at $1.32, which typically means lower liquidity and higher susceptibility to technical selling, algorithmic rebalancing, or sector-wide pressure. Micro-cap and penny stocks often move sharply on thin volume without corresponding news coverage. Possible explanations include profit-taking after a recent run, portfolio rebalancing by institutional holders, sector weakness in healthcare or consumer goods (depending on CABR's business), or a delayed disclosure that has not yet appeared in major news aggregators. Without access to message boards, SEC filings dated today, or insider transaction alerts, pinpointing the cause is speculative.

BDL

Flanigan's Enterprises, Inc.Consumer Cyclical

$41.60−$5.03

-10.8%

AMEX · Mkt cap $86 M

No financial news appeared in the last 48 hours, so the cause of BDL's 10.79% decline cannot be determined from available headlines. The drop likely stems from earnings results, guidance revision, sector weakness, or market-wide factors not captured in the provided news feed.

Flanigan's Enterprises is a casual dining operator with limited analyst coverage on major financial platforms. The absence of any news headlines in the Yahoo Finance RSS feed over the past 48 hours is notable but does not mean no catalyst occurred. Restaurants are sensitive to labor cost inflation, food commodity prices, consumer spending weakness, and same-store sales trends. A single-day drop of this magnitude in a stock ranked 49 biggest loser typically reflects material company-specific or sector news. Without access to earnings releases, conference call transcripts, SEC filings, or financial news wires beyond the provided feed, the specific driver remains unknown. The timing could involve quarterly results, analyst downgrades, comparable-restaurant sales misses, or broader restaurant sector underperformance that simply has not yet appeared in the headline feed.

BYSI

BeyondSpring Inc.Healthcare

$1.49−$0.18

-10.8%

NASDAQ · Mkt cap $30 M

BeyondSpring fell 10.78% on July 9, 2026, but no news headlines were available in the prior 48 hours to explain the decline, leaving the specific catalyst unclear.

With no recent news provided, the cause of BYSI's sharp 10.78% drop cannot be pinned to a specific event such as earnings, clinical trial results, regulatory action, or guidance change. BeyondSpring is a clinical-stage biotech company, a sector highly sensitive to clinical data releases, FDA decisions, and funding announcements. The decline could reflect a delayed market reaction to earlier news not captured in the 48-hour window, a broader biotech sector selloff, short-covering reversal, or an unannounced development such as a clinical setback or insider selling that has not yet been publicly disclosed. Without contemporaneous headlines, attributing the move to any particular cause would be speculation.